“No generics, Doctor!” The perspective of general practitioners in two French regions
Tóm tắt
Generic medicines are essential to controlling health expenditures. Their market share is still small in France. The discourse and practices of prescribers may play a major role in their use. The purpose of this study was to explore the knowledge, attitudes and practices of general practitioners (GPs) toward generic medicines in two French regions with the lowest penetration rate of these products. An observational study was carried out from October 2015 to February 2016 in Guadeloupe and Martinique. The first qualitative phase involved a diversified sample of 14 GPs who underwent semi-structured interviews. The second phase involved a random sample of 316 GPs (response rate = 74%) who were administered a structured questionnaire developed from the results of the first phase. Seventy-eight percent of the participants defined a generic drug as a drug containing an active substance identical to a brand-name drug, but only 11% considered generic drugs to be equivalent to brand-name drugs, and the same proportion believed that the generic drugs were of doubtful quality. The primary recognized advantage of generic medicines was their lower cost (82%). The main drawbacks cited were the variability of their presentation (44%), the confusion that they caused for some patients (47%), frequent allegations of adverse side effects (37%) and a lack of efficacy (24%), and frequent refusal by patients (26%). Seventy-four percent of the participants stated that they adapted their prescribing practices to the situation, and of this group, 47% prescribed the originator product simply on demand. Most surveyed GPs were not hostile towards generic medicines. They were caught between the requirements of health insurance regimes and the opposition of numerous users and suggested that the patient information provided by health authorities should be improved and that drug composition and packaging should be made uniform.
Tài liệu tham khảo
Organisation for Economic Co-operation and Development. Statistics/OECD Health Statistics [Internet]. [cited 2017 Jul 28]; Available from: doi:10.1787/health-data-en
OECD. Health at a Glance 2015: OECD indicators [internet]. Paris: OECD publishing; 2015 [cited 2017 Jul 27]. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en
IMS Institute for Healthcare Informatics. The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective [Internet]. Parsippany, NJ 07054, USA: imshealth; 2015 [cited 2017 Jul 29]. Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/IIHI_Generics_Healthcare_Brief.pdf
Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. Definition and classification of generic drugs across the world. Appl Health Econ Health Policy. 2015;13(Suppl 1):S5–11.
World Health Organization. The WHO expert committee on specifications for pharmaceutical preparations [Internet]. Geneva: [cited 2017 Jul 29]. Available from: http://www.who.int/medicines/publications/BrochurePharmaupdatedversion.pdf
Imbaud D, Morin A, Picard S, Toujas F. Evaluation de la politique française des médicaments génériques [Internet]. Inspection générale des affaires sociales; 2015 [cited 2017 Jul 29]. Available from: http://www.igas.gouv.fr/IMG/pdf/RM2012-115P_-_DEF_sans_sign.pdf
Dylst P, Vulto A, Simoens S. Analysis of French generic medicines retail market: why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res. 2014;14:795–803.
Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open. 2015;5:e008915.
Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173.
Lagarce L, Lusson-Brisset C, Bruhat C, Diquet B, Lainé-Cessac P. How practitioners view generic drugs: an opinion study from general practitioners in Maine-et-Loire (France). Therapie. 2005;60:67–74.
Paraponaris A, Verger P, Desquins B, Villani P, Bouvenot G, Rochaix L, et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Policy. 2004;70:23–32.
Journal Officiel de la République Française. Arrêté du 28 novembre 2014 portant approbation de l’avenant n° 8 à l’accord national relatif à la fixation d’objectifs de délivrance de spécialités génériques [Internet]. Legifrance [cited 2017 Jul 29];Available from: https://www.legifrance.gouv.fr/eli/arrete/2014/11/28/AFSS1420398A/jo/texte
Olalla LA, Chovelon R, Lewis K, Carrère P. Pas de générique docteur ! [Internet]. 2015 [cited 2017 Jul 29];Available from: http://dumas.ccsd.cnrs.fr/dumas-01254066/document
Kelly-Irving M, Mulot S, Inamo J, Ruidavets J-B, Atallah A, Lang T. Improving stroke prevention in the French West Indies: limits to lay knowledge of risk factors. Stroke. 2010;41:2637–44.
C@rtoSanté. Geoclip Serveur O3 [Internet]. L’offre et le recours aux soins en un clic [cited 2017 Aug 5];Available from: http://cartosante.atlasante.fr/#v=map5;l=en
Hassali MA, Kong DCM, Stewart K. Generic medicines: perceptions of general practitioners in Melbourne, Australia. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2006;3:214–25.
Chua GN, Hassali MA, Shafie AA, Awaisu AA. Survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy. 2010;95:229–35.
Gossell-Williams M. Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. West Indian Med J. 2007;56:458–63.
Polinski JM, Maclure M, Marshall B, Cassels A, Agnew-Blais J, Patrick AR, et al. Does knowledge of medication prices predict physicians’ support for cost effective prescribing policies. Can J Clin Pharmacol. 2008;15:e286–94.
O’Leary A, Usher C, Lynch M, Hall M, Hemeryk L, Spillane S, et al. Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Res Notes. 2015;8:790.
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–26.
Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, et al. The impact of generic substitution on health and economic outcomes: a systematic review. Appl Health Econ Health Policy. 2015;13(Suppl 1):S21–33.
Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45:31–8.
Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract. 2014;31:467–74.
Lieb K, Scheurich A. Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One. 2014;9:e110130.
Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD, Kochen MM, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43:472–9.
Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20:185–91.
Sarradon-Eck A, Blanc M-A, Faure M. Users sceptical about generic drugs: an anthropological approach. Rev Epidemiol Sante Publique. 2007;55:179–85.
Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff (Millwood). 2009;28:546–56.
Kersnik J, Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther. 2006;31:577–83.
Toverud E-L, Hartmann K, Håkonsen HA. Systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy. 2015;13(Suppl 1):S35–45.
Cour des Comptes. La sécurité sociale - Rapport sur l’application des lois de financement de la sécurité sociale [Internet]. 2014 [cited 2017 Jul 29]. Available from: http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/154000643.pdf
Moran V, Checkland K, Coleman A, Spooner S, Gibson J, Sutton M. General practitioners’ views of clinically led commissioning: cross-sectional survey in England. BMJ Open. 2017;7:e015464.
Bosa IM. Ethical budgets: a critical success factor in implementing new public management accountability in health care. Health Serv Manag Res. 2010;23:76–83.
Le Pen C. The drug budget silo mentality: the French case. Value Health. 2003;6:S10–9.